10.8K
Downloads
220
Episodes
From Wall Street’s opening bell to market close.
Episodes
Wednesday Oct 18, 2023
Wednesday Oct 18, 2023
Bell2Bell’s latest podcast features Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD), along with Buzz Woods from Corporate Communications, who join the podcast to share insights into the biopharmaceutical company's groundbreaking work in novel anti-purinergic drug therapies (APT) for neurologic conditions, primarily Autism Spectrum Disorder (ASD).
Explore the comprehensive interview on the Bell2Bell Podcast, where PaxMedica, Inc., a prominent clinical-stage biopharmaceutical firm, provides valuable perspectives on its innovative initiatives and visionary advancements in the sphere of novel anti-purinergic drug therapies. Gain an exclusive understanding of PaxMedica's pioneering efforts in neurology and biopharmaceutical breakthroughs, with a special emphasis on advancements in treating Autism Spectrum Disorder (ASD) and other neurologic conditions, as Howard Weisman, Chairman and CEO, and Buzz Woods from Corporate Communications, offer a compelling overview of the company's recent achievements and future objectives.
Join the highly acclaimed host, Bell2Bell's Stuart Smith, and Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD) and Buzz Woods Corporate Communications, to learn more about the company’s recent milestones and operational goals for the balance of 2023 and beyond.